Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a stronger radiation blast beat aggressive prostate cancer?

NCT ID NCT00967863

Ongoing Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial asks whether giving a higher dose of radiation (80 Gy) is better than the standard dose (70 Gy) for men with aggressive prostate cancer who are also receiving hormone therapy. The study includes about 500 men with unfavorable prostate cancer features, such as advanced stage, high Gleason score, or elevated PSA. Researchers will compare how long men live without their cancer progressing, as well as side effects and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
radiation therapy (3D conformal or intensity-modulated)
What this could lead to
If successful, this could establish a higher radiation dose as a more effective standard for aggressive prostate cancer, potentially improving long-term control and survival.
What could go wrong
The trial is large but results are not yet known. Higher radiation doses may increase side effects, and the benefit over the standard dose could be small or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

  • CHU Henri Mondor

    Créteil, 94010, France

  • Centre Alexis Vautrin

    Vandœuvre-lès-Nancy, 54511, France

  • Centre Azureen de Cancerologie

    Mougins, 06250, France

  • Centre CARIO - HPCA

    Plérin, 22190, France

  • Centre Eugène Marquis

    Rennes, 35042, France

  • Centre Francois Baclesse

    Caen, 14076, France

  • Centre Henri Becquerel

    Rouen, 76038, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69310, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Centre Paul Strauss

    Strasbourg, 67065, France

  • Centre Rene Gauducheau

    Saint-Herblain, 44800, France

  • Centre Val D'Aurelle

    Montpellier, 34298, France

  • Centre de Cancérologie du Grand Montpellier

    Montpellier, 34070, France

  • Centre hospitalier Métropole Savoie

    Chambéry, 73011, France

  • Ch Bretonneau

    Tours, 37044, France

  • Chr Orleans

    Orléans, 45000, France

  • Clinique Léonard de Vinci

    Chambray-lès-Tours, 37175, France

  • Clinique PASTEUR

    Toulouse, 31076, France

  • Hia Begin

    Saint-Mandé, 94160, France

  • Hopital La Timone

    Marseille, 13386, France

  • Hôpital Jean Bernard - CHU de Poitiers

    Poitiers, 86021, France

  • Hôpital Saint Louis

    Paris, 75010, France

  • Institut Bergonie

    Bordeaux, 33076, France

  • Institut de Cancérologie LUCIEN NEUWIRTH

    Saint-Priest-en-Jarez, 42270, France

  • Institut de Cancérologie de l'Ouest Paul Papin

    Angers, 49933, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.